Income before deduction of interest, taxes and amortization: Skye Bioscience (SKYE)

Graphic logo of skyebioscience.com (SKYE)

Compliance with environmental standards in laboratories is driving growth, and EBITDA fluctuations on GURU.Markets reflect this trend, where the value of 0.00 expresses the metric level. Skye Bioscience, Inc. (SKYE) is developing a synthetic cannabinoid system to combat obesity. The global scaling of innovative formulas ensures high margins. This chart demonstrates real cash flow compared to historical data.

SKYE Skye Bioscience, Inc. Profit before payment of interest, taxes and amortization (11/23/2025 - 11/13/2026)

Skye Bioscience, Inc. - analytical breakdowns and key metrics (SKYE)

- market price and analyst price targets:
Stock Price Skye Bioscience Inc.|SKYE - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Skye Bioscience|SKYE - Total Company Value
- book capitalization information:
Accounting Value per Share Skye Bioscience|SKYE - Company Book Value|Market Capitalization to Book Value skyebioscience.com|SKYE - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Skye Bioscience, Inc.|SKYE - Long-Term Debt to Equity Ratio|Current Liabilities to Capital skyebioscience.com|SKYE - Company Aggregate Debts|Debts to Book Value Skye Bioscience|SKYE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Skye Bioscience|Quick Liquidity skyebioscience.com
- earnings and multiples data:
SKYE - Net Profit|Company Profit Forecast Skye Bioscience, Inc.|SKYE - Price to Earnings Ratio|Projected Price to Earnings Ratio Skye Bioscience Inc.|SKYE - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Skye Bioscience|SKYE - Operating profit EBITDA|Net earnings per share for the last 12 months Skye Bioscience|SKYE - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months skyebioscience.com|SKYE - Earnings growth in current year|Expected net earnings per share growth next year Skye Bioscience, Inc.
Summary company analytics:Skye Bioscience, Inc.
Original product of Skye Bioscience, Inc.

This metric measures the amount of cash generated by the core business before deducting depreciation and interest, reflecting the actual efficiency of the operating cycle. Analyzing EBITDA history allows for an assessment of the risks of acquiring an asset at peak earnings, which is particularly critical for Skye Bioscience (SKYE) during the automation of molecule screening via robotic manipulators to accelerate the development of cannabinoid drugs.

Competitor analysis for Skye Bioscience, Inc.

Operating profit EBITDA Indivior Corp INDV|COLL - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CRON (thecronosgroup.com)|Canopy Growth Corporation (CGC) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization High Tide Inc|Profit before payment of interest, taxes and amortization Aurora Cannabis, Inc.|Achieve Life Sciences Inc (ACHV) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Anebulo Pharmaceuticals (ANEB)|Operating profit EBITDA intercure.co (INCR)|Nutriband - Operating profit before deduction of amortization|Nasus Pharma Ltd. (NSRX) - Profit before interest, taxes and amortization|IGC Pharma Inc - Operating profit EBITDA|Profit before interest, taxes and amortization MIRA Pharmaceuticals|FLGC (Flora Growth Corp.) - Operating profit before deduction of amortization|IM Cannabis - Income before deduction of interest, taxes and amortization|ADIL (Adial Pharmaceuticals Inc.) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization ARTL|Operating profit EBITDA ENSC|Operating income before deduction of amortization titanpharm.com|Profit before payment of interest, taxes and amortization Greenlane Holdings GNLN|inmedpharma.com (INM) - Profit before interest, taxes and amortization|AKAN - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Enveric Biosciences Inc ENVB|BGXX: Operating profit EBITDA|Operating profit before deduction of amortization Hempacco Co Inc.